Perrigo (PRGO) Asset Writedowns and Impairment (2015 - 2026)
Perrigo's (PRGO) quarterly Asset Writedowns and Impairment came in at $330.8 million in Q1 2026, up 10570.97% year-on-year from N/an in Q1 2025, and down 75.65% on a QoQ basis from $1.4 billion in Q4 2025.
Perrigo (PRGO) Asset Writedowns and Impairment (2015 - 2026) Analysis & Trends
Perrigo (PRGO) has 11 years of Asset Writedowns and Impairment data on file, last reported at $330.8 million in Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment rose 10570.97% year-over-year to $330.8 million in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 1183.83% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 1433.3% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $330.8 million, down from $1.4 billion in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for PRGO reached as high as $1.4 billion in Q4 2025 and fell as low as $1.5 million in Q2 2025.
- Historically, Asset Writedowns and Impairment has averaged $234.1 million across 4 years, with a median of $36.4 million in 2024.
- Across the five-year window, Asset Writedowns and Impairment sank 95.6% in 2025 and surged 10570.97% in 2026, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $90.0 million in 2023, then plunged by 57.11% to $38.6 million in 2024, then jumped by 3419.43% to $1.4 billion in 2025, then slumped by 75.65% to $330.8 million in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $330.8 million in Q1 2026, $1.4 billion in Q4 2025, and $1.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 330.80 Mn |
| Mar 28, 2026 | 330.80 Mn |
| Dec 31, 2025 | 1.36 Bn |
| Dec 31, 2025 | 1.36 Bn |
| Jun 28, 2025 | 1.50 Mn |
| Jun 28, 2025 | 1.50 Mn |
| Mar 29, 2025 | 3.10 Mn |
| Mar 29, 2025 | 3.10 Mn |
| Dec 31, 2024 | 38.60 Mn |
| Dec 31, 2024 | 38.60 Mn |
| Sep 28, 2024 | 16.20 Mn |
| Sep 28, 2024 | 16.20 Mn |
| Jun 29, 2024 | 34.10 Mn |
| Jun 29, 2024 | 34.10 Mn |
| Dec 31, 2023 | 90.00 Mn |
| Dec 31, 2023 | 90.00 Mn |
| Dec 31, 2021 | 11.00 Mn |
| Dec 31, 2021 | 11.00 Mn |
| Oct 2, 2021 | 3.50 Mn |
| Oct 2, 2021 | 3.50 Mn |